{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:07:01Z","timestamp":1789150021343,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003495","name":"Hessisches Ministerium f\u00fcr Wissenschaft und Kunst","doi-asserted-by":"publisher","award":["LOEWE1\/16\/519\/03\/09.001(0009)\/98"],"award-info":[{"award-number":["LOEWE1\/16\/519\/03\/09.001(0009)\/98"]}],"id":[{"id":"10.13039\/501100003495","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopsych.2025.02.903","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T18:48:39Z","timestamp":1741459719000},"page":"333-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1379-9491","authenticated-orcid":false,"given":"Jonathan","family":"Repple","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Bayas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"M\u00f6ser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nene F.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2025.02.903_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5","year":"2013"},{"key":"10.1016\/j.biopsych.2025.02.903_bib3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National comorbidity Survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2025.02.903_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112846","article-title":"Predictors of quality of life in bipolar disorder: A path analytical study","volume":"285","author":"Cotrena","year":"2020","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2025.02.903_bib5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jad.2012.08.045","article-title":"Quality of life among patients with bipolar disorder in primary care versus community mental health settings","volume":"146","author":"Miller","year":"2013","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2025.02.903_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jad.2020.09.061","article-title":"Quality of life and clinical outcomes in bipolar disorder: An 8-year longitudinal study","volume":"278","author":"Khafif","year":"2021","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2025.02.903_bib7","series-title":"S3-Leitlinie zur Diagnostik und Therapie Bipolarer St\u00f6rungen","author":"Bauer","year":"2019"},{"key":"10.1016\/j.biopsych.2025.02.903_bib8","year":"2019"},{"key":"10.1016\/j.biopsych.2025.02.903_bib9","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(13)60857-0","article-title":"Treatment of bipolar disorder","volume":"381","author":"Geddes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2025.02.903_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40345-018-0133-9","article-title":"Antidepressants in bipolar depression: An enduring controversy","volume":"6","author":"Gitlin","year":"2018","journal-title":"Int J Bipolar Disord"},{"key":"10.1016\/j.biopsych.2025.02.903_bib12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/bmj.39197.619190.80","article-title":"Onset of action of antidepressants","volume":"334","author":"Tylee","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.biopsych.2025.02.903_bib13","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00213-021-05825-8","article-title":"Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis","volume":"238","author":"Conley","year":"2021","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.biopsych.2025.02.903_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.02.903_bib15","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2025.02.903_bib16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2025.02.903_bib17","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/14740338.2022.2047928","article-title":"Efficacy and safety of racemic ketamine and esketamine for depression: A systematic review and meta-analysis","volume":"21","author":"Bahji","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.biopsych.2025.02.903_bib18","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: A randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.02.903_bib19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bdi.12487","article-title":"Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial","volume":"19","author":"Grunebaum","year":"2017","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.biopsych.2025.02.903_bib20","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1038\/s41380-022-01757-7","article-title":"International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators","volume":"27","author":"Price","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.02.903_bib21","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/bdi.12277","article-title":"A single infusion of ketamine improves depression scores in patients with anxious bipolar depression","volume":"17","author":"Ionescu","year":"2015","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.biopsych.2025.02.903_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13651501.2017.1297834","article-title":"Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression","volume":"21","author":"Rybakowski","year":"2017","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1016\/j.biopsych.2025.02.903_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","article-title":"Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression","volume":"106","author":"Zheng","year":"2018","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2025.02.903_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1674","article-title":"Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression \u2013 An open-label three-week pilot study","volume":"10","author":"Zhuo","year":"2020","journal-title":"Brain Behav"},{"key":"10.1016\/j.biopsych.2025.02.903_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jad.2020.06.020","article-title":"A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression","volume":"275","author":"Zheng","year":"2020","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2025.02.903_bib26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jad.2020.09.056","article-title":"Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression","volume":"278","author":"Delfino","year":"2021","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2025.02.903_bib27","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2147\/NDT.S325000","article-title":"Intravenous ketamine infusions in treatment-resistant bipolar depression: An open-label naturalistic observational study","volume":"17","author":"Wilkowska","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.biopsych.2025.02.903_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/bdi.13284","article-title":"Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression","volume":"25","author":"Fancy","year":"2023","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.biopsych.2025.02.903_bib29","first-page":"420","article-title":"Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression","volume":"21","author":"Fancy","year":"2023","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"10.1016\/j.biopsych.2025.02.903_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.euroneuro.2024.04.014","article-title":"Ketamine treatment for anhedonia in unipolar and bipolar depression: A systematic review","volume":"86","author":"Kwa\u015bny","year":"2024","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2025.02.903_bib31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/bdi.13296","article-title":"Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression","volume":"25","author":"Martinotti","year":"2023","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.biopsych.2025.02.903_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jad.2023.02.151","article-title":"Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study","volume":"330","author":"Leal","year":"2023","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2025.02.903_bib33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpsychires.2023.06.028","article-title":"Arketamine for bipolar depression: Open-label, dose-escalation, pilot study","volume":"164","author":"Bandeira","year":"2023","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2025.02.903_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/14728214.2021.1898588","article-title":"Efficacy of dextromethorphan for the treatment of depression: A systematic review of preclinical and clinical trials","volume":"26","author":"Majeed","year":"2021","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.biopsych.2025.02.903_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112750","article-title":"Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"284","author":"Yao","year":"2020","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2025.02.903_bib36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.biopsych.2004.11.023","article-title":"An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression","volume":"57","author":"Zarate","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.02.903_bib37","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/npp.2009.191","article-title":"Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole","volume":"35","author":"Brennan","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.02.903_bib38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/JCP.0000000000000693","article-title":"A double-blind, placebo-controlled, pilot study of riluzole monotherapy for acute bipolar depression","volume":"37","author":"Park","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.02.903_bib39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41398-023-02514-2","article-title":"Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder","volume":"13","author":"Cutler","year":"2023","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2025.02.903_bib40","article-title":"Antidepressants plus benzodiazepines for adults with major depression","volume":"6","author":"Ogawa","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.biopsych.2025.02.903_bib41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000486696","article-title":"Benzodiazepines as a monotherapy in depressive disorders: A systematic review","volume":"87","author":"Benasi","year":"2018","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.biopsych.2025.02.903_bib42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41386-023-01721-1","article-title":"Novel neurosteroid therapeutics for post-partum depression: Perspectives on clinical trials, program development, active research, and future directions","volume":"49","author":"Patterson","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.02.903_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/pcn.13569","article-title":"Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial","volume":"77","author":"Kato","year":"2023","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2025.02.903_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41386-023-01751-9","article-title":"Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: Results from the phase 3 CORAL study","volume":"49","author":"Parikh","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.02.903_bib45","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14445","article-title":"Zuranolone in major depressive disorder: Results from MOUNTAIN-A Phase 3, multicenter, double-blind, randomized, placebo-controlled trial","volume":"84","author":"Clayton","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2025.02.903_bib46","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.2147\/DDDT.S240856","article-title":"Review of allopregnanolone agonist therapy for the treatment of depressive disorders","volume":"15","author":"Walkery","year":"2021","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.biopsych.2025.02.903_bib47","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/npp.2014.138","article-title":"A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression","volume":"39","author":"Brown","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.02.903_bib48","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.3390\/ijms21217942","article-title":"The basal pharmacology of palmitoylethanolamide","volume":"21","author":"Rankin","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.biopsych.2025.02.903_bib49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jad.2018.02.057","article-title":"Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial","volume":"232","author":"Ghazizadeh-Hashemi","year":"2018","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2025.02.903_bib50","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/pcn.13441","article-title":"Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial","volume":"76","author":"Abedini","year":"2022","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2025.02.903_bib51","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/070674370505000703","article-title":"Flashback: Psychiatric experimentation with LSD in historical perspective","volume":"50","author":"Dyck","year":"2005","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.02.903_bib52","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2025.02.903_bib53","series-title":"LSD: My Problem Child","author":"Hofmann","year":"2013"},{"key":"10.1016\/j.biopsych.2025.02.903_bib54","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: Past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.02.903_bib55","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.02.903_bib56","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.02.903_bib57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.biopsych.2025.02.903_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.122993","article-title":"Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial","volume":"460","author":"Schindler","year":"2024","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.biopsych.2025.02.903_bib59","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","article-title":"Exploratory controlled study of the migraine-suppressing effects of psilocybin","volume":"18","author":"Schindler","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.biopsych.2025.02.903_bib60","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2025.02.903_bib61","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.02.903_bib62","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231198466","article-title":"History repeating: Guidelines to address common problems in psychedelic science","volume":"13","author":"van Elk","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.02.903_bib63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/02698811221131997","article-title":"Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of \u2018magic mushroom\u2019 consumption","volume":"37","author":"Morton","year":"2023","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.02.903_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279073","article-title":"\u201cA sense of the bigger picture:\u201d A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use","volume":"17","author":"DellaCrosse","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2025.02.903_bib65","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","article-title":"Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar Type II major depressive episodes: A nonrandomized open-label trial","volume":"81","author":"Aaronson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.02.903_bib66","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.medj.2024.01.005","article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin","volume":"5","author":"Rosenblat","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.biopsych.2025.02.903_bib67","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/a-1524-2794","article-title":"Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: An analysis of online psychedelic experience reports","volume":"54","author":"Nayak","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.biopsych.2025.02.903_bib68","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","article-title":"Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)","volume":"99","author":"Rickli","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2025.02.903_bib69","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2025.02.903_bib70","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1360-0443.2006.01652.x","article-title":"Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids","volume":"102","author":"Gable","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2025.02.903_bib71","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archpsyc.63.10.1121","article-title":"Antidepressant efficacy of the antimuscarinic drug scopolamine: A randomized, placebo-controlled clinical trial","volume":"63","author":"Furey","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2025.02.903_bib72","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.biopsych.2009.11.021","article-title":"Replication of scopolamine\u2019s antidepressant efficacy in major depressive disorder: A randomized, placebo-controlled clinical trial","volume":"67","author":"Drevets","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.02.903_bib73","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40263-022-00964-8","article-title":"Clinical effectiveness of muscarinic receptor-targeted interventions in neuropsychiatric disorders: A systematic review","volume":"36","author":"Vaidya","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopsych.2025.02.903_bib74","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/WNF.0b013e318278b703","article-title":"Scopolamine as an antidepressant: A systematic review","volume":"36","author":"Jaffe","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.biopsych.2025.02.903_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.837671","article-title":"The kappa Opioid receptor: A promising therapeutic target for multiple pathologies","volume":"13","author":"Dalefield","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.biopsych.2025.02.903_bib76","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: A multicriteria decision analysis","volume":"376","author":"Nutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2025.02.903_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102799","article-title":"Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: Observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial","volume":"76","author":"Erritzoe","year":"2024","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.biopsych.2025.02.903_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109422","article-title":"Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment","volume":"226","author":"Johnston","year":"2023","journal-title":"Neuropharmacology"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322325010194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322325010194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:01:28Z","timestamp":1778745688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322325010194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0006322325010194"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2025.02.903","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2025.02.903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}